Niagen Bioscience Highlights Preclinical Research Linking CD38-Driven NAD+ Depletion To Placental Aging; NOTE: Niagen Bioscience Did Not Conduct, Fund, Or Design This Study, And The NR Used Was Not The Company’s Niagen Ingredient
Preclinical study results showcase that CD38, an NAD-consuming enzyme more active with age and inflammation, leads to NAD+ depletion in placental tissue, while restoring NAD+ with the precursor NR improved placental,